1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2023

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2023

  • March 2015
  • -
  • GlobalData
  • -
  • 82 pages

Summary

Table of Contents

Search Inside

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2023

Summary

AD is an irreversible, neurodegenerative brain disease of the elderly, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity. Similar to AD, mild cognitive impairment (MCI) is also a condition of the elderly in which there is a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia.

To forecast the total prevalent cases of AD in adults ages =60 years in the 9MM during the forecast period (2013-2023), GlobalData epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD. Similarly, to forecast the total prevalent cases of MCI in the 9MM, GlobalData’s epidemiologists selected country-specific studies that defined MCI as a “slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia.” Additionally, GlobalData epidemiologists kept the forecast methodology consistent across the 9MM in order to allow for a meaningful comparison of the total prevalent cases between the markets.

GlobalData epidemiologists forecast that by 2023, there will be approximately 17.38 million total prevalent cases of AD across the 9MM covered in this analysis. GlobalData epidemiologists expect a 34.3% increase in the total prevalent cases of AD in the 9MM over the next decade. Similarly, GlobalData epidemiologists forecast that the total prevalent cases of MCI in the 9MM will increase from 82.25 million cases in 2013 to 108.41 million cases in 2013 at a decadal growth rate of 31.80%.

Scope

- The Alzheimer’s disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). The series also includes a 10-year epidemiological forecast for the total prevalent cases of AD segmented by sex, age, and severity in these markets. In addition, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age in these markets.
- The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
- Identify the percentage of AD prevalent cases by severity and identify the number of cases with MCI.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.